Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700230 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
A Phase 1 study of Neurofibromatosis Type 1 and Recurrent Malignant Peripheral Nerve Sheath Tumor, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02700230: Completed Phase 1 study of Neurofibromatosis Type 1 and Recurrent Malignant Peripheral Nerve Sheath Tumor, sponsored by Mayo Clinic.
NCT02700230 is a Phase 1 study of Neurofibromatosis Type 1 and Recurrent Malignant Peripheral Nerve Sheath Tumor that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants, below the 160-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02700230, a Phase 1 study of Neurofibromatosis Type 1 and Recurrent Malignant Peripheral Nerve Sheath Tumor, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and the best dose of a vaccine therapy in treating patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent). Vaccines made from a gene-modified virus may kill tumor cells expressing a gene called neurofibromin 1 (NF1) without affecting surrounding normal cells and may also help the body build an effective immune response to kill tumor cells.
Primary Outcome
Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and dose level).
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Single Photon Emission Computed Tomography
- BIOLOGICAL Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-03-22 |
| Est. Completion | 2024-04-17 |
| Phase | Phase 1 |
What the finished NCT02700230 record still lists
NCT02700230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 160-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Neurofibromatosis Type 1 appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT02700230 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02700230 about?
NCT02700230 is a clinical study titled "Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery". This phase I trial studies the side effects and the best dose of a vaccine therapy in treating patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent). Vaccines made from a gene-modified virus m...
What is the current status of trial NCT02700230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2017-03-22. Estimated completion is 2024-04-17.
What conditions does trial NCT02700230 study?
This clinical trial studies the following conditions: Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor, Metastatic Malignant Peripheral Nerve Sheath Tumor.
What interventions are being tested in trial NCT02700230?
The interventions under investigation include: Computed Tomography (PROCEDURE), Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Single Photon Emission Computed Tomography (PROCEDURE), Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (BIOLOGICAL).
Who is sponsoring clinical trial NCT02700230?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02700230 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02700230's enrollment target sits among peer trials
9 18th of 17 the lowest of 17 other Neurofibromatosis Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurofibromatosis Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
ACTIVE NOT RECRUITING · Phase 1
-
Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
RECRUITING · NA
-
Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study
RECRUITING
-
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI